COMP <GO>
KEQU vs JNJ // GROSS PROFIT MARGIN
Kewaunee Scientific Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: KEQU 4
— JNJ 7
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $33.51 (-3.48%) • MKT CAP: $97.0M
gross-margins
28.50%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KEQU VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KEQU | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 28.50% | 67.90% | -39.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.70% | 25.50% | -8.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.3x | 18.5x | -12.20 | KEQU | /valuation <GO> |
| Free Cash Flow Yield | 19.20% | 2.97% | +16.23 | KEQU | /fcf-yield <GO> |
| Operating Margin | 5.90% | 34.70% | -28.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 28.50% | -25.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 17.30% | 6.00% | +11.30 | KEQU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.37 | 5.59 | -2.22 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 62.1 | -12.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 23.0x | -14.50 | KEQU | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $97.0M | $662.49B | -$662.39B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KEQU REV | JNJ REV | KEQU GROSS % | JNJ GROSS % | KEQU FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $282.0M | $94.19B | 28.5% | 67.9% | $18.6M | $19.70B |
| FY 2024 | $240.5M | $88.82B | 28.6% | 69.1% | $14.8M | $19.84B |
| FY 2023 | $203.8M | $85.16B | — | — | $19.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KEQU // BETA —
JNJ // BETA 1.08